A NEW PARADIGM FOR TARGETING MUTANT P53 TUMOURS
Grant number: 1120293 | Funding period: 2017 - 2020
Over half of all cancers contain mutations in a gene called TP53, also known as the “guardian of the genome”. Mutation of TP53 provides tumour cells with a growth advantage, and leads to resistance to chemotherapy and poor outcomes for patients. We have identified a potential “Achilles heel” in cancers with TP53 mutations. In this project we will establish a new paradigm for treating tumours with TP53 mutations that will be applicable to a large number of patients across all types of cancer.
Related publications (4)
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Sophia Ceder, Sofi E Eriksson, Emarndeena H Cheteh, Swati Dawar, Mariana Corrales Benitez, Vladimir JN Bykov, Kenji M Fujihara, Melodie Grandin, Xiaodun Li, Susanne Ramm, Corina Behrenbruch, Kaylene J Simpson, Frederic Hollande, Lars Abrahmsen, Nicholas J Clemons, Klas G Wiman
The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. The compound APR-246 (PRIMA-1Met/Eprenetapopt) is co..
GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma
Jovana R Gotovac, David SH Liu, Michael J Yates, Julia Milne, Arthi A Macpherson, Kaylene J Simpson, Guy D Eslick, Catherine Mitchell, Cuong P Duong, Wayne A Phillips, Nicholas J Clemons
Efficacious therapeutic approaches are urgently needed to improve outcomes in patients with oesophageal adenocarcinoma (OAC). Howe..
Inhibiting the system x((C)over-bar)/glutathione axis selectively targets cancers with mutant-p53 accumulation
David S Liu, Cuong P Duong, Sue Haupt, Karen G Montgomery, Colin M House, Walid J Azar, Helen B Pearson, Oliver M Fisher, Matthew Read, Glen R Guerra, Ygal Haupt, Carleen Cullinane, Klas G Wiman, Lars Abrahmsen, Wayne A Phillips, Nicholas J Clemons